Litigation Details for UCB, Inc. v. Actavis Laboratories UT, Inc. (D. Del. 2019)
✉ Email this page to a colleague
UCB, Inc. v. Actavis Laboratories UT, Inc. (D. Del. 2019)
| Docket | ⤷ Try a Trial | Date Filed | 2019-03-05 |
| Court | District Court, D. Delaware | Date Terminated | |
| Cause | 35:271 Patent Infringement | Assigned To | Kent A. Jordan |
| Jury Demand | None | Referred To | |
| Parties | UCB, INC. | ||
| Patents | 10,130,589; 6,884,434 | ||
| Attorneys | Thomas F. Fleming | ||
| Firms | Wilson Sonsini Goodrich & Rosati | ||
| Link to Docket | External link to docket | ||
Small Molecule Drugs cited in UCB, Inc. v. Actavis Laboratories UT, Inc.
The small molecule drug covered by the patents cited in this case is ⤷ Try a Trial .
Details for UCB, Inc. v. Actavis Laboratories UT, Inc. (D. Del. 2019)
| Date Filed | Document No. | Description | Snippet | Link To Document |
|---|---|---|---|---|
| 2020-09-16 | 135 | Opinion - Memorandum Opinion | claims of U.S. Patent No. 10,130,589 (the "'589 Patent"), the patent asserted by the… regarding related patents, U.S. Patent Nos. 6,884,434 (the "'434 Patent") and 8,232,…quot;'414 Patent"), and held the '414 Patent invalid and the '434 Patent valid and … Book patents related to Neupro® to determine whether any of them were 'blocking patents[,]"…and fourth, UCB's other patents did not function as blocking patents. (D.I. 110 at 4-5.) | External link to document |
| 2019-08-02 | 18 | Notice of Service | Initial Infringement Contentions for U.S. Patent No. 10,130,589 B2 filed by LTS Lohmann Therapie-Systeme… 6 March 2019 1:19-cv-00474 835 Patent - Abbreviated New Drug Application(ANDA) None | External link to document |
| 2021-04-07 | 196 | Judgment | 2, 3, 7, 10, 11, and 12 of U.S. Patent No. 10,130,589 (the '589 Patent) are invalid.. Signed by Judge …3, 7, 10, 11, and 12 of U.S. Patent No. 10,130,589 (the '589 Patent) are invalid. SO…for relief requested in Plaintiffs' Complaint for Patent Infringement D.I. 1 are denied with prejudice; …relief requested in Plaintiffs' Complaint for Patent Infringement (D.I. 1) are denied with prejudice… 6 March 2019 1:19-cv-00474 835 Patent - Abbreviated New Drug Application(ANDA) None | External link to document |
| 2019-09-03 | 25 | Notice of Service | Invalidity Contentions with Respect to U.S. Patent No. 10,130,589 filed by Actavis Laboratories UT, Inc..(… 6 March 2019 1:19-cv-00474 835 Patent - Abbreviated New Drug Application(ANDA) None | External link to document |
| 2019-03-05 | 4 | Patent/Trademark Report to Commissioner of Patents | the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 10,130,589 B2. (nmg) (Entered… 6 March 2019 1:19-cv-00474 835 Patent - Abbreviated New Drug Application(ANDA) None | External link to document |
| 2020-02-06 | 80 | Opinion - Memorandum Opinion | infringement of U.S. Patent No. 10,130,589 (the "' 589 Patent"). (D.I. 1) The patent-in-suit relates…quot;It is a bedrock principle of patent law that the claims of a patent define the invention to which the…reading the entire patent." Id at 1321 (internal quotation marks omitted). The patent "specification…of the ' 589 patent, and, thus, should be limiting. See, e.g., ' 589 patent at 3:12-36, 5:22…preamble term was not relied on during patent prosecution as being patentably significant or to distinguish | External link to document |
| >Date Filed | >Document No. | >Description | >Snippet | >Link To Document |
